This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Rosetta Genomics And Collaborators Demonstrate MicroRNAs Accurately Sub-Classify Renal Tumors

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled “Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression” has been published in the online version of The Journal of Molecular Diagnostics. The study demonstrates the ability of microRNAs to accurately identify four histological types of renal tumors, namely clear cell, papillary, and chromophobe renal cell carcinoma, as well as oncocytoma, a benign tumor. The study is available online at: http://jmd.amjpathol.org/cgi/content/abstract/jmoldx.2010.090187v1

The current classification of renal cell carcinoma includes four main types: conventional (clear cell), papillary, chromophobe, and collecting duct carcinoma, as well as unclassified renal cell carcinoma. Oncocytoma, papillary adenoma, mesonephric adenoma and angiomyolipoma are the main benign tumors in the kidney.

The publication describes a study of microRNA expression profiles in more than 120 renal tumor samples. Six microRNA biomarkers that are specifically expressed in the four most common histological types of renal tumors were identified, and were used to design an algorithm to classify these tumors. This classifier had 93% accuracy in diagnosing an independent test set of renal tumors.

The different histological subtypes of Renal Cell Carcinoma (RCC) vary in their clinical course and their prognosis. Patients with Clear-Cell RCC have a poorer prognosis, and differences may also exist between the prognosis of patients with papillary and chromophobe RCC (Non-Clear Cell).

Initial studies show differences in responses of RCC subtypes to targeted therapies, and future therapies may be individualized for each type. The accurate identification of these subtypes may play an important role in patient management and in the selection of patients for clinical trials of RCC drugs in development.

“Treatment options for RCC have increased significantly over the past decade, with targeted therapies playing an important role in this transformation. As with other types of cancers, the medical community is realizing the importance of accurate cancer subclassification for treatment choice and response for RCC,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. “Efforts are being made to understand which patients may benefit from particular therapies and to design targeted therapies to specific cancer subtypes. As demonstrated in this recent publication, microRNAs are powerful biomarkers that can accurately differentiate subtypes of RCC and have the potential to be used to for helping to target therapies to the appropriate RCC subtype.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs